| __timestamp | Amphastar Pharmaceuticals, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 28427000 | 46425000 |
| Thursday, January 1, 2015 | 37065000 | 81491000 |
| Friday, January 1, 2016 | 41199000 | 94291000 |
| Sunday, January 1, 2017 | 43415000 | 121827000 |
| Monday, January 1, 2018 | 57564000 | 160524000 |
| Tuesday, January 1, 2019 | 68853000 | 200000000 |
| Wednesday, January 1, 2020 | 67229000 | 275000000 |
| Friday, January 1, 2021 | 60932000 | 328100000 |
| Saturday, January 1, 2022 | 74771000 | 463800000 |
| Sunday, January 1, 2023 | 73741000 | 565000000 |
| Monday, January 1, 2024 | 731100000 |
In pursuit of knowledge
In the competitive landscape of biopharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Neurocrine Biosciences, Inc. and Amphastar Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D investments.
Neurocrine Biosciences has consistently outpaced Amphastar, with its R&D expenses growing by over 1,100% from 2014 to 2023. This surge reflects a strategic focus on developing groundbreaking therapies. In contrast, Amphastar's R&D spending increased by approximately 160% during the same period, indicating a more conservative approach.
By 2023, Neurocrine's R&D expenses were nearly eight times higher than Amphastar's, underscoring its aggressive pursuit of innovation. This trend highlights the varying strategies within the industry, where some companies prioritize rapid advancement, while others maintain steady, incremental growth.
Who Prioritizes Innovation? R&D Spending Compared for AbbVie Inc. and Neurocrine Biosciences, Inc.
Vertex Pharmaceuticals Incorporated or Neurocrine Biosciences, Inc.: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Zoetis Inc. and Amphastar Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Verona Pharma plc
Neurocrine Biosciences, Inc. or CymaBay Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development Expenses Breakdown: Neurocrine Biosciences, Inc. vs Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Soleno Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Novavax, Inc.
Research and Development Expenses Breakdown: Intra-Cellular Therapies, Inc. vs Amphastar Pharmaceuticals, Inc.
Comparing Innovation Spending: Rhythm Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.